Radiotherapy for non-small cell lung cancer: evolution and development

doi:10.19401/j.cnki.1007-3639.2020.10.008

Welcome to China Oncology,

China Oncology ›› 2020, Vol. 30 ›› Issue (10): 777-784.doi: 10.19401/j.cnki.1007-3639.2020.10.008

• Specialists’ Commentary and Article • Previous Articles Next Articles

Radiotherapy for non-small cell lung cancer: evolution and development

XU Xinyan ¹ , CHEN Jiayan ¹ , MAO Jingfang ^{1, 2} , FAN Min¹#br#

1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; 2. Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai 201321, China

Online:2020-10-30 Published:2020-11-12
Contact: FAN Min E-mail: fanming@fudan.edu.cn

Share article

Abstract

Abstract: Lung cancer is the leading cause of tumor-related death worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85% of all cases of lung cancer. Radiotherapy has long been one of the fundamental therapeutic approaches for lung cancer. Over the years, with the ever-accelerated development of radiotherapy technology and the deepened basic and clinical research on NSCLC, the application of radiotherapy in lung cancer treatment has been dramatically expanded, with a promising landscape for future development.

Key words: Lung cancer, Radiotherapy, Progress

XU Xinyan , CHEN Jiayan , MAO Jingfang , FAN Min . Radiotherapy for non-small cell lung cancer: evolution and development[J]. China Oncology, 2020, 30(10): 777-784.

[1]	WANG Manli, CHEN Hui, DUAN Zhi, XU Qimei, LI Zhen. A study on communication mechanism of lung cancer cells in tumor microenvironment mediated by pleckstrin-2/miR-196a signal axis [J]. China Oncology, 2024, 34(7): 628-638.
[2]	QIAN Bin, CHEN Haiquan. Important progress in surgical treatment of lung cancer in 2023 [J]. China Oncology, 2024, 34(4): 335-339.
[3]	FENG Zheng, GUO Qinhao, ZHU Jun, WU Xiaohua, WEN Hao. Progress in treatment of gynecological cancer in 2023 [J]. China Oncology, 2024, 34(4): 340-360.
[4]	LIN Yicong, WANG Yue, XUE Qianqian, ZHENG Qiang, JIN Yan, HUANG Ziling, LI Yuan. Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications [J]. China Oncology, 2024, 34(4): 368-379.
[5]	XU Yonghu, XU Dazhi. Progress and prospects of gastric cancer treatment in the 21st century [J]. China Oncology, 2024, 34(3): 239-249.
[6]	WANG Xuefei, ZHOU Peng, TANG Zhaoqing. New progress and development trend of surgical treatment for gastric cancer [J]. China Oncology, 2024, 34(3): 250-258.
[7]	JIANG Mengqi, HAN Yuchen, FU Xiaolong. Research progress on H-E stained whole slide image analysis by artificial intelligence in lung cancer [J]. China Oncology, 2024, 34(3): 306-315.
[8]	ZHANG Qi, XIU Bingqiu, WU Jiong. Progress of important clinical research of breast cancer in China in 2023 [J]. China Oncology, 2024, 34(2): 135-142.
[9]	ZHANG Siyuan, JIANG Zefei. Important research progress in clinical practice for advanced breast cancer in 2023 [J]. China Oncology, 2024, 34(2): 143-150.
[10]	HU Xiaoyu, CAI Yuwen, YE Fugui, SHAO Zhimin, HU Weigang, YU Keda. Impact of BRCA1/2 germline mutation on the incidence of second primary cancer following postoperative radiotherapy in patients with triple-negative breast cancer [J]. China Oncology, 2024, 34(2): 185-190.
[11]	LIU Zhiyu, XU Dong, CHEN Xihao, LI Jipeng. Influencing factors and establishment of a prediction model for the tumor regression after neoadjuvant chemoradiotherapy in locally advanced rectal cancer [J]. China Oncology, 2024, 34(2): 191-200.
[12]	CHEN Hongyu, SU Pengyu, LUO Wenzi, PANG Dequan, WANG Feiran. A study of relationship between cardiac exposure dose-volume and cardiovascular autonomic dysfunction in radiotherapy [J]. China Oncology, 2024, 34(11): 1036-1044.
[13]	CUI Jianchun, LU Wei, LI Qianyong. Clinical application value of surface-guided automatic positioning in pelvic tumor radiotherapy [J]. China Oncology, 2024, 34(10): 966-971.
[14]	LI Tong, YANG Huijuan. Progress in diagnosis and treatment of mucinous ovarian cancer [J]. China Oncology, 2024, 34(1): 90-96.
[15]	WU Han, YANG Zhangru, FENG Wen, ZENG Wanqin, GUO Jindong, LI Hongxuan, WANG Changlu, WANG Jiaming, LÜ Changxing, ZHANG Qin, YU Wen, CAI Xuwei, FU Xiaolong. The efficacy and prognosis analysis after stereotactic body radiotherapy for multiple primary early-stage lung cancer [J]. China Oncology, 2023, 33(9): 844-856.

Radiotherapy for non-small cell lung cancer: evolution and development

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments